Chicago, IL – According to filings with the U.S. Securities and Exchange Commission, Vanqua Bio is raising $84,999,987.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, James Sullivan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Vanqua Bio
Vanqua Bio is helping usher in a new era of hope for the millions of people living with neurodegenerative diseases. Our unique drug-development approach is designed to overcome longstanding challenges in the neuroscience field by capitalizing on the power of human genetics to identify genes that cause or increase the risk of neurodegenerative disease. We leverage novel, proprietary research tools and in vitro modeling of disease, based on patient-derived neuronal cells, to develop transformative therapies that slow or stop the progression of Parkinsons disease (PD), Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS) and Gaucher disease (GD).

To learn more about Vanqua Bio, visit http://www.vanquabio.com/

Contact:
James Sullivan, Chief Executive Officer
773-360-1673
https://www.linkedin.com/in/jim-sullivan-92576411/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved